Perrigo Company PLC

Perrigo's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. The company's liquidity position is mixed, with $531.6 million in cash and equivalents, but a negative net cash position after subtracting total debt. Free cash flow is negative at -$1.32 billion, suggesting that capital expenditures and other operational needs are outpacing cash generation. Profitability metrics are weak, with a net loss of $1.43 billion and an operating loss of $1.16 billion. Return on equity is -48.56%, and return on assets is -16.7%, both significantly below industry norms. Gross profit of $1.49 billion represents a 35.1% margin, which is in line with the industry median, but the company's inability to convert this into operating profit highlights operational inefficiencies. Geographically, Perrigo's revenue is concentrated in North America and Europe, with no detailed segment breakdown provided in the available data. The company's exposure to these regions may limit its ability to diversify risk, particularly in light of regulatory and pricing pressures in the pharmaceutical sector. Growth prospects are muted, with no specific revenue growth rates provided. The company's operating cash flow of $238.5 million is insufficient to cover its free cash flow deficit, indicating a need for external financing or operational improvements. The absence of a clear growth trajectory is compounded by the current net loss and negative returns on equity and assets. Risk factors include liquidity constraints and the potential for operational underperformance. The company's liquidity risk is rated as medium, and while dilution risk is currently low, the negative net cash position and high debt levels could necessitate future equity or debt financing. No dilution sources are explicitly identified in the available data. Recent events include a continued focus on cost management and restructuring efforts, as reflected in the operating loss and negative net income. Analysts have assigned a mean price target of $16.50, with a median of $16.50, suggesting a potential upside from the current market price of $11.33. However, the lack of strong buy recommendations and the presence of three hold ratings indicate cautious sentiment among analysts.